These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Palmer AM Trends Pharmacol Sci; 2011 Mar; 32(3):141-7. PubMed ID: 21256602 [TBL] [Abstract][Full Text] [Related]
7. Novel disease-modifying therapies for Alzheimer's disease. Jiang T; Yu JT; Tan L J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013 [TBL] [Abstract][Full Text] [Related]
8. Novel insights for the treatment of Alzheimer's disease. Kurz A; Perneczky R Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):373-9. PubMed ID: 20655969 [TBL] [Abstract][Full Text] [Related]
9. Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. Plangár I; Zádori D; Klivényi P; Toldi J; Vécsei L J Alzheimers Dis; 2011; 24 Suppl 2():199-209. PubMed ID: 21441658 [TBL] [Abstract][Full Text] [Related]
10. Status and future directions of clinical trials in Alzheimer's disease. Plascencia-Villa G; Perry G Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics in Alzheimer's disease. Cacabelos R Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236 [TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease and amyloid: culprit or coincidence? Skaper SD Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic targets in Alzheimer's disease and related tauopathies. Corbo CP; Alonso Adel C Prog Mol Biol Transl Sci; 2011; 98():47-83. PubMed ID: 21199770 [TBL] [Abstract][Full Text] [Related]
14. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Hampel H; Schneider LS; Giacobini E; Kivipelto M; Sindi S; Dubois B; Broich K; Nisticò R; Aisen PS; Lista S Expert Rev Neurother; 2015 Jan; 15(1):83-105. PubMed ID: 25537424 [TBL] [Abstract][Full Text] [Related]
15. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. McClean PL; Hölscher C Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293 [TBL] [Abstract][Full Text] [Related]
16. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors. Mota SI; Ferreira IL; Rego AC Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316 [TBL] [Abstract][Full Text] [Related]
17. Beyond amyloid: the future of therapeutics for Alzheimer's disease. Lane RF; Shineman DW; Steele JW; Lee LB; Fillit HM Adv Pharmacol; 2012; 64():213-71. PubMed ID: 22840749 [TBL] [Abstract][Full Text] [Related]
18. Emerging amyloid and tau targeting treatments for Alzheimer's disease. Khan A; Corbett A; Ballard C Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214 [TBL] [Abstract][Full Text] [Related]